The Novartis collaboration process has been structured to permit thorough and thoughtful review by a team of scientific and business experts to provide responses in a timely and efficient manner.

All major therapeutic and technical areas have a dedicated Strategic Alliance Manager, who is an expert in the field and manages the entire evaluation and collaboration process.
The Strategic Alliance Manager:
 

• Identifies the company or academic center.
• Leads or, in later-stage projects, supports Pharma Business Development & Licensing negotiations.
• Manages the relationship with our collaborators over the long term to ensure an interactive and productive relationship.   

Key stages of our process
 

The aim of Strategic Alliances is to conduct a rapid and efficient, but thorough evaluation of every potential opportunity:
 

• First, we evaluate non-confidential data.
• If we decide to proceed in the review process, companies are invited to present to a scientific team.
• If appropriate, a confidentiality agreement (CDA) is signed, confidential data is reviewed, and scientific, legal and financial due diligence is conducted.
  In some cases a material transfer agreement (MTA) is put in place to permit in-house evaluation of a compound or technology.
• Subject to internal review, we then proceed to negotiation and contract finalization.

After contract signing, the Strategic Alliance Manager remains actively involved with the collaboration to ensure its mutual success.